| 000 | 01660 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250515013146.0 | ||
| 264 | 0 | _c20060504 | |
| 008 | 200605s 0 0 eng d | ||
| 022 | _a0269-2813 | ||
| 024 | 7 |
_a10.1111/j.1365-2036.2006.02748.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLee, S S | |
| 245 | 0 | 0 |
_aTreating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice. _h[electronic resource] |
| 260 |
_bAlimentary pharmacology & therapeutics _cFeb 2006 |
||
| 300 |
_a397-408 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntiviral Agents _xtherapeutic use |
| 650 | 0 | 4 | _aCanada |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHepatitis C, Chronic _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInterferon alpha-2 |
| 650 | 0 | 4 |
_aInterferon-alpha _xtherapeutic use |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPolyethylene Glycols _xtherapeutic use |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aRecombinant Proteins |
| 650 | 0 | 4 |
_aRibavirin _xtherapeutic use |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aBain, V G | |
| 700 | 1 | _aPeltekian, K | |
| 700 | 1 | _aKrajden, M | |
| 700 | 1 | _aYoshida, E M | |
| 700 | 1 | _aDeschenes, M | |
| 700 | 1 | _aHeathcote, J | |
| 700 | 1 | _aBailey, R J | |
| 700 | 1 | _aSimonyi, S | |
| 700 | 1 | _aSherman, M | |
| 773 | 0 |
_tAlimentary pharmacology & therapeutics _gvol. 23 _gno. 3 _gp. 397-408 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1365-2036.2006.02748.x _zAvailable from publisher's website |
| 999 |
_c16038813 _d16038813 |
||